Literature DB >> 8608778

Papillary thyroid carcinoma. Etiology, assessment, and therapy.

K B Ain1.   

Abstract

Most papillary carcinomas do not cause death or significant morbidity. Current modes of therapy when appropriately applied, appear effective for 80% to 90% of patients. The clinical challenge is to identify the minority of patients who will suffer greatly from tumors to direct appropriately the best therapeutic efforts. New appreciation of histologic subtypes of papillary carcinoma has provided fresh clues to identify cancers with poor prognosis. We look forward to innovative therapies to deal with currently untreatable disease.

Entities:  

Mesh:

Year:  1995        PMID: 8608778

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  16 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Thyroid nodules and other incidentalomas: we must search for evidence and clarify our ethical priorities.

Authors:  J Raymond; Ho Long
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

3.  Thyroid carcinoma in patients with Graves' disease: an institutional experience.

Authors:  Shuanzeng Wei; Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

4.  MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Authors:  Ying C Henderson; Yunyun Chen; Mitchell J Frederick; Stephen Y Lai; Gary L Clayman
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

5.  High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.

Authors:  I Martínez; A Mantilla; M E Medrano; R Hernández; D M Hernández; M Lazos; H Santiago; B González; A Hidalgo; M Salcedo
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Evaluation of diagnostic efficiency of computerized image analysis based quantitative nuclear parameters in papillary and follicular thyroid tumors using paraffin-embedded tissue sections.

Authors:  N Gupta; C Sarkar; R Singh; A K Karak
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Src inhibitors in suppression of papillary thyroid carcinoma growth.

Authors:  Ying C Henderson; Rafael Toro-Serra; Yunyun Chen; Junsun Ryu; Mitchell J Frederick; Ge Zhou; Gary E Gallick; Stephen Y Lai; Gary L Clayman
Journal:  Head Neck       Date:  2013-06-01       Impact factor: 3.147

9.  Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Poorni M Manohar; Lauren J Beesley; Emily L Bellile; Francis P Worden; Anca M Avram
Journal:  Clin Nucl Med       Date:  2018-09       Impact factor: 7.794

10.  Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma.

Authors:  Y Kapran; N Ozbey; S Molvalilar; E Sencer; F Dizdaroğlu; S Ozarmağan
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.